PHARMACEUTICAL RESEARCH IN MOLECULAR ONCOLOGY

被引：116
作者：
GIBBS, JB
OLIFF, A
机构：
[1] Department of Cancer Research Merck Research Laboratories West Point
来源：
CELL | 1994年 / 79卷 / 02期
关键词：
D O I：
10.1016/0092-8674(94)90189-9
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
[No abstract available]
引用
收藏
页码：193 / 198
页数：6
相关论文
共 40 条
[11]  
Freidinger R M, 1993, Prog Drug Res, V40, P33
[12]   A SPECIFIC INHIBITOR OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE [J].
FRY, DW ;
KRAKER, AJ ;
MCMICHAEL, A ;
AMBROSO, LA ;
NELSON, JM ;
LEOPOLD, WR ;
CONNERS, RW ;
BRIDGES, AJ .
SCIENCE, 1994, 265 (5175) :1093-1095
[13]  
FRY DW, 1994, EXPERT OPIN INV DRUG, V3, P577
[14]  
Gibbs J B, 1992, Semin Cancer Biol, V3, P383
[15]   FARNESYLTRANSFERASE INHIBITORS - RAS RESEARCH YIELDS A POTENTIAL CANCER THERAPEUTIC [J].
GIBBS, JB ;
OLIFF, A ;
KOHL, NE .
CELL, 1994, 77 (02) :175-178
[16]  
Gilman AG., 1990, J MED CHEM, V8th, DOI DOI 10.1021/acs.jmedchem.8b01308
[17]  
GOULD RJ, 1994, DRUG DISCOVERY DESIG, V1, P537
[18]   CONFORMATIONAL SHIFTS PROPAGATE FROM THE OLIGOMERIZATION DOMAIN OF P53 TO ITS TETRAMERIC DNA-BINDING DOMAIN AND RESTORE DNA-BINDING TO SELECT P53 MUTANTS [J].
HALAZONETIS, TD ;
KANDIL, AN .
EMBO JOURNAL, 1993, 12 (13) :5057-5064
[19]  
Harris William, 1993, Drugs of the Future, V18, P727
[20]  
HUBER HE, 1994, CURR MED CHEM, V1, P13
1234